Giving an IVIG infusion involves careful preparation, a slow rate titration, and close monitoring throughout. The process typically takes two to six hours depending on the dose, the patient’s tolerance, and whether it’s a first or repeat infusion. While the specifics vary by product and clinical setting, the core steps follow a consistent sequence: screen the patient, prepare the product, start slowly, increase the rate in stages, and watch for reactions.
Pre-Infusion Screening
Before the first IVIG dose, patients need bloodwork to check their IgA levels. People with very low IgA (below 7 mg/dL) can develop antibodies against IgA, which puts them at risk for severe allergic reactions during infusion. Roughly 25 to 30% of IgA-deficient individuals carry these antibodies. If the patient falls into this group, the prescribing provider will select an IgA-depleted product or consider subcutaneous immunoglobulin instead.
Baseline labs also typically include kidney function tests, since IVIG can stress the kidneys. Patients over 65, those with diabetes, high blood pressure, or existing kidney problems need extra caution throughout the process.
Hydration and Pre-Medication
Good hydration is one of the simplest ways to reduce complications. All patients should drink extra fluids in the hours before and after infusion. For higher-risk patients, IV pre-hydration with 500 to 1,000 mL of normal saline before the infusion helps protect the kidneys, lowers the chance of blood clots, and may prevent the severe headaches (aseptic meningitis) that some patients develop after treatment.
Pre-medication protocols vary. A common approach is to give a steroid (hydrocortisone, 50 to 200 mg IV) before the first infusion day. Patients with a history of migraines or prior infusion reactions often receive acetaminophen and an antihistamine as well. Some facilities pre-medicate every session; others only do so for the initial dose and then reassess based on tolerance.
Preparing the Product
IVIG products are stored refrigerated and must reach room temperature before use. This can take up to 60 minutes, so pull the vials out well ahead of time. Never microwave or heat them artificially. Each vial is single-use: any product left over after the infusion must be discarded.
Most liquid IVIG formulations do not require an inline filter. The exception is Gammagard S/D, a lyophilized (powdered) product that needs reconstitution and must be administered through a 15-micron filter, typically using the infusion set included by the manufacturer. For all other products, a standard IV administration set is sufficient.
Calculating the Dose
IVIG is dosed in grams per kilogram of body weight. Standard dosing uses the patient’s actual body weight, even in obese patients. Some facilities have experimented with dosing based on ideal body weight to reduce cost, but the prevailing recommendation remains actual weight, with adjustments made over time based on clinical response. The total dose for a treatment cycle (often 1 to 2 g/kg) may be split across consecutive days to keep each session’s volume manageable.
Starting the Infusion and Titrating Up
The infusion always begins slowly and is increased in steps. For a standard-risk patient with normal kidney function who has tolerated IVIG before, a typical protocol looks like this:
- Starting rate: 0.5 mL/kg/hour
- Titration: Double the rate every 15 to 30 minutes if tolerated
- Maximum rate: 4 mL/kg/hour, with some providers allowing up to 8 mL/kg/hour in select patients
For higher-risk patients (those over 65, with kidney impairment, or receiving sucrose-containing formulations), the parameters are more conservative:
- Starting rate: 0.3 mL/kg/hour
- Titration: Double every 15 to 30 minutes as tolerated
- Maximum rate: 2.4 mL/kg/hour
Patients with migraine history should be capped at roughly 6 grams per hour regardless of weight-based calculations.
In practice, hospitals vary considerably in their titration schedules. A cross-institutional review found starting rates ranging from 0.3 to 0.6 mL/kg/hour and maximum rates anywhere from 2 to 8 mL/kg/hour. The safest approach for a first infusion is always to start at the low end and increase cautiously.
Monitoring During the Infusion
Vital signs (temperature, blood pressure, heart rate, respiratory rate) should be taken at baseline, and then checked frequently during the first infusion. Most reactions occur during the initial dose or within the first 30 to 60 minutes of a rate increase. If the first dose goes smoothly with no adverse effects, subsequent infusions generally only require baseline vitals, though many facilities continue periodic checks as a precaution.
Watch the patient closely each time you increase the rate. If any symptoms develop, pause the titration. If symptoms are mild and resolve, you can resume at the previous tolerated rate.
Recognizing and Managing Reactions
Most IVIG reactions are mild and stop once the infusion is slowed or paused. Common symptoms include flushing, headache, chills, fever, fatigue, and general achiness. These are often rate-related, meaning they happen when the infusion speed exceeds what the patient can comfortably tolerate.
The standard response to a mild reaction is to stop or slow the infusion, let the symptoms resolve, and then restart at a lower rate. Many patients who react during their first infusion tolerate future doses well once the right rate is established.
More serious reactions are rare but important to recognize:
- Aseptic meningitis: Persistent severe headache, nausea, vomiting, sensitivity to light, and fever, usually appearing within 24 hours of infusion
- Kidney injury: Decreased urine output, swelling, or rapid weight gain in the days following treatment
- Blood clots: Sudden leg swelling, chest pain, or shortness of breath
- Heart rhythm changes: Palpitations, rapid or unusually slow heart rate, particularly in patients with pre-existing heart disease
- Hemolytic anemia: Unusual fatigue, dark urine, or yellowing skin in the days after infusion
Patients who experience repeated or severe reactions to IVIG may be candidates for switching to subcutaneous immunoglobulin, which delivers smaller, more frequent doses under the skin and tends to cause fewer systemic side effects.
After the Infusion
Once the infusion is complete, continue monitoring the patient for a period before they leave. There is no universally fixed observation time, but most facilities keep patients for at least 15 to 30 minutes after the infusion ends, longer for first-time recipients or anyone who experienced symptoms during the session.
Encourage continued fluid intake after treatment. Delayed effects like headache, fatigue, or mild flu-like symptoms are common in the first 24 to 48 hours and generally resolve on their own. Patients should know to report any severe headache, decreased urination, chest pain, or signs of unusual bleeding or bruising in the days that follow.